Biocon reported Q4FY26 operating revenue of Rs 4,517 Cr (up 10% YoY adjusted) and FY26 revenue of Rs 16,927 Cr (up 13% YoY adjusted), with EBITDA margin expanding ~200 bps to 22% for the full year. The Board approved acquisition of the remaining ~2% of BBL via a share swap of up to 87,92,317 Biocon shares at Rs 376.16 each (totalling Rs 330.73 Crores), conversion of OCDs and CCDs into BBL equity, a new LTIP, change in statutory auditors to S. R. Batliboi & Associates LLP, and a final dividend of Re. 0.50 per share.
Biocon Q4FY26 & FY26 Results: Revenue Up 10% YoY; Key Corporate Actions Approved
